MBI-226 Micrologix/Fujisawa

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations

Abstract

Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated.

Original languageEnglish (US)
Pages (from-to)999-1003
Number of pages5
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number8
StatePublished - Aug 1 2003

Fingerprint

Dive into the research topics of 'MBI-226 Micrologix/Fujisawa'. Together they form a unique fingerprint.

Cite this